SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Gujarat Terce Laboratories Ltd

BSE: 524314 NSE: ISIN: INE499G01013
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Gujarat Terce Laboratories Ltd belong to?
Gujarat Terce Laboratories Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Gujarat Terce Laboratories Ltd a good quality company?
Gujarat Terce Laboratories Ltd is a quality company, based on a 10 year financial track record.
Q.3 Is Gujarat Terce Laboratories Ltd undervalued or overvalued?
Gujarat Terce Laboratories Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Gujarat Terce Laboratories Ltd a good buy now?
Gujarat Terce Laboratories Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd revenue growth is 4.7% for FY-2025 , which is below its 5 year CAGR of 6% , indicating slower growth.
Q.2 Gross Profit margin of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd Gross profit margin which is the profit after deduction of direct costs, is 7.5% for FY-2025 , which is above its 5 year median of 1.9% , indicating increasing margins.
Q.3 Operating Profit Margin of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 7.74% for FY-2025 , which is above its 5 year median of 2.64% indicating increasing margins.
Q.4 Net Profit Margin of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd Net Profit Margin is -1.95% for FY-2025 , is in line with with its 5 year median of -1.95%, indicating stable margins.
Current Level Historic Median
Gross Profit Margin 7.5 1.9
Operating Profit Margin 7.74 2.64
Net Profit Margin -1.95 -1.95
Q.5 Return on Asset of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd Return on Asset is -4.4%, which is in line with its 5 year historical median of -4.4%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd Return on equity is -14.79% for FY-2025 , which is in line with its historical median of -14.79%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd Return on capital employed is 41.39% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd Cash conversion cycle is 30 days, below its historical median of 48 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 2.26 1.73
ROE -14.79 -14.79
ROCE 41.39 8.31
Cash Conversion Cycle 30 days 48 days
Q.9 Debt to Equity ratio of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd Debt-to-Equity ratio is 0.15 , which is in line with the industry average of 0.15 , indicating similar to debt levels in the industry.
Q.10 Debt to cash flow from operations of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd Debt to cash flow from operations is 0.31 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Gujarat Terce Laboratories Ltd?
Promoters hold 40.03% of the Gujarat Terce Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Gujarat Terce Laboratories Ltd vs industry peers?
Gujarat Terce Laboratories Ltd revenue CAGR is 5.98% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 50.2 137.1
Gross Profit 3.8 15.1
Operating Profit 3.9 16
Net Profit -1 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 2.26 0.8
ROE -14.79 8.91
ROCE 41.39 11.59
Cash Conversion Cycle (days) 30.28 76

Valuation & price assessment

Q.1 Stock return of Gujarat Terce Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 17.7% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 17.7% 40.8% 30% -31.7%
Q.3 Valuation ratios of Gujarat Terce Laboratories Ltd vs historical?
The current P/E is similar that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings - 0.00 40.28
Price to Book 2.74 0.76 2.77
Price to Sales 0.55 0.23 2.65
EV to EBITDA 6 0.00 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×